Gene and Cell Therapies Targeting CNS Disorders Pipeline Analysis Report 2026

Report Coverage

The Gene and Cell Therapies Targeting CNS Disorders Pipeline Analysis Report by Expert Market Research gives comprehensive insights into gene and cell therapies targeting CNS disorders therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for gene and cell therapies targeting CNS disorders. The gene and cell therapies targeting CNS disorders report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The gene and cell therapies targeting CNS disorders pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with gene and cell therapies targeting CNS disorders treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to Gene and Cell Therapies Targeting CNS Disorders.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Gene and Cell Therapies Targeting CNS Disorders Pipeline Outlook

The gene and cell therapies targeting CNS disorders pipeline is advancing rapidly as developers focus on one-time, disease-modifying treatments for inherited and neurodegenerative neurological disorders. Gene replacement, gene editing, and cell-based regenerative approaches are expanding therapeutic possibilities for conditions with limited treatment options. A major milestone occurred in March 2024, when the U.S. FDA approved Lenmeldy™ (atidarsagene autotemcel), the first gene therapy for children with certain forms of metachromatic leukodystrophy. This approval underscores the growing regulatory momentum and continued innovation driving the CNS gene and cell therapy landscape.

Gene and Cell Therapies Targeting CNS Disorders Epidemiology

Gene and cell therapies targeting CNS disorders are being developed for neurological diseases with a substantial and increasing global burden. In the United States, approximately 7.1 million people are living with Alzheimer's disease and related dementias, while Parkinson's disease affects about 1 million individuals, with prevalence expected to rise as the population ages. Rare CNS disorders, including Huntington's disease, amyotrophic lateral sclerosis (ALS), and inherited leukodystrophies, collectively contribute to the growing demand for innovative gene and cell therapies targeting unmet neurological needs.

Gene and Cell Therapies Targeting CNS Disorders – Pipeline Therapeutic Assessment

Gene and Cell Therapies Targeting CNS Disorders Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, the pipeline is evenly distributed across phase I (33.33%), phase II (33.33%) and phase III (33.33%). This balanced distribution reflects sustained clinical development across early, mid, and late-stage programs, highlighting continued investment in advancing innovative gene and cell therapies targeting CNS disorders toward potential regulatory approval and commercialization.

Gene and Cell Therapies Targeting CNS Disorders Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the gene and cell therapies targeting CNS disorders pipeline analysis include small molecules, monoclonal antibodies and gene therapies. The gene and cell therapies targeting CNS disorders report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for gene and cell therapies targeting CNS disorders. In November 2024, The U.S. FDA approved Kebilidi™ (eladocagene exuparvovec) from PTC Therapeutics for the treatment of AADC deficiency, becoming the first FDA-approved gene therapy delivered directly into the brain. The adeno-associated virus (AAV)-based therapy restores AADC enzyme production and represents a major advance in treating rare CNS genetic disorders.

Gene and Cell Therapies Targeting CNS Disorders Clinical Trials – Key Players

The EMR report for the gene and cell therapies targeting CNS disorders pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed gene and cell therapies targeting CNS disorders therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in gene and cell therapies targeting CNS disorders clinical trials:

• Iambic Therapeutics, Inc.
• Sangamo Therapeutics
• Voyager Therapeutics
• uniQure N.V.
• Neurocrine Biosciences
• BlueRock Therapeutics
• Aspa Therapeutics
• Abeona Therapeutics
• Lexeo Therapeutics
• Capsida Biotherapeutics
• Passage Bio
• NKGen Biotech

Gene and Cell Therapies Targeting CNS Disorders – Emerging Drugs Profile

Key Questions Answered in the Gene and Cell Therapies Targeting CNS Disorders Pipeline Insight Report

• Which companies/institutions are leading the gene and cell therapies targeting CNS disorders drug development?
• Which company is leading the gene and cell therapies targeting CNS disorders pipeline development activities?
• What is the current gene and cell therapies targeting CNS disorders commercial assessment?
• What are the opportunities and challenges present in the gene and cell therapies targeting CNS disorders pipeline landscape?
• What is the efficacy and safety profile of gene and cell therapies targeting CNS disorders pipeline drugs?
• Which company is conducting major trials for gene and cell therapies targeting CNS disorders drugs?
• Which companies/institutions are involved in gene and cell therapies targeting CNS disorders collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in gene and cell therapies targeting CNS disorders?

Reasons To Buy This Report

The Gene and Cell Therapies Targeting CNS Disorders Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for gene and cell therapies targeting CNS disorders. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into gene and cell therapies targeting CNS disorders collaborations, regulatory environments, and potential growth opportunities.

Related Reports

Clinical Trials Market

CNS Lymphoma Epidemiology Forecast

CNS Lymphoma Pipeline Analysis Report

Central Nervous System (CNS) Stimulant Drugs Market